F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
52 hedge funds and large institutions have $52.9M invested in F-star Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 15 increasing their positions, 5 reducing their positions, and 7 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 5
186% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 7
33% more funds holding
Funds holding: 39 → 52 (+13)
10% less capital invested
Capital invested by funds: $59M → $52.9M (-$6.09M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.28M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.06M |
| 3 |
Axa
Paris,
France
|
+$1.48M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$647K |
| 5 |
Bank of New York Mellon
New York
|
+$522K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.14M |
| 2 |
Millennium Management
New York
|
-$1.41M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$642K |
| 4 |
HCM
Highbridge Capital Management
New York
|
-$615K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$313K |
FSTX Hedge Fund Activity: Q2 2018 in Review
52 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q2 2018, worth a combined $52.9M — down 10% from $59M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new FSTX positions and 7 closed out — a net gain of 13 holders — while 15 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock, adding an estimated $6.28M. The largest seller was Alyeska Investment Group, cutting an estimated $2.14M.
- 52 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q2 2018, up from 39 in Q1 2018.
- Funds reported $52.9M of F-star Therapeutics, Inc. Common Stock stock for Q2 2018, down 10% quarter-over-quarter.
- 20 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q2 2018 and 7 closed out, a net change of +13 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q2 2018 was BlackRock, an estimated $6.28M added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q2 2018 was Alyeska Investment Group, an estimated $2.14M sold.
Based on aggregated 13F filings for Q2 2018.